Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?

Vadim Tchaikovski1, Gregory Y H Lip

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham, B18 7QH, England, UK.

Insights

Concerns about cancer risks with antihypertensive drugs, specifically angiotensin receptor blockers (ARBs), have resurfaced. This review synthesizes current evidence to assess if ARBs increase cancer risk.

Area of Science:

  • Pharmacology and Oncology
  • Cardiovascular Drug Safety

Background:

  • Antihypertensive therapies, particularly angiotensin receptor blockers (ARBs), have faced scrutiny regarding potential carcinogenic side effects.
  • Regulatory bodies in the US and Europe have re-examined evidence linking ARBs to cancer risk.

Purpose of the Study:

  • To comprehensively review and synthesize current multidisciplinary evidence on the association between ARBs and tumorigenesis.
  • To address the ongoing debate regarding the safety of ARBs concerning cancer development.

Main Methods:

  • Review of existing scientific literature, including basic science and preclinical studies.
  • Analysis of data from three meta-analyses and one nationwide cohort study.
  • Synthesis of contemporary, multidisciplinary evidence.

Main Results:

  • Evidence from basic science, preclinical studies, meta-analyses, and cohort studies was evaluated.
  • The review consolidates findings to assess the link between ARBs and cancer risk.
  • Contemporary data is summarized to inform the ongoing safety discussion.

Conclusions:

  • The review provides a summary of current evidence regarding ARBs and cancer risk.
  • It aims to clarify the association between this class of antihypertensive medications and potential tumorigenesis.
  • Findings will contribute to the ongoing assessment of ARB safety by regulatory agencies and clinicians.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...